Cargando…
Novel coronavirus disease in patients with end‐stage kidney disease
The novel coronavirus disease outbreak started in Wuhan, China, in December 2019 and has since spread rapidly worldwide. As almost all patients with end‐stage kidney disease have been treated with HD in Japan, they have a higher risk of infection than the healthy population. Moreover, the complicati...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675310/ https://www.ncbi.nlm.nih.gov/pubmed/33040443 http://dx.doi.org/10.1111/1744-9987.13599 |
_version_ | 1783611656331329536 |
---|---|
author | Shimada, Noriaki Shimada, Hiroaki Itaya, Yoshiaki Tomino, Yasuhiko |
author_facet | Shimada, Noriaki Shimada, Hiroaki Itaya, Yoshiaki Tomino, Yasuhiko |
author_sort | Shimada, Noriaki |
collection | PubMed |
description | The novel coronavirus disease outbreak started in Wuhan, China, in December 2019 and has since spread rapidly worldwide. As almost all patients with end‐stage kidney disease have been treated with HD in Japan, they have a higher risk of infection than the healthy population. Moreover, the complications of renal failure, such as hypertension and cardiovascular diseases, appear to be a risk factor of death owing to novel coronavirus disease. The reported morbidity and mortality rates of novel coronavirus disease are significantly higher in dialysis patients than in the healthy population. No treatment for novel coronavirus disease has yet been developed; thus, countermeasures to prevent the spread of coronavirus disease in dialysis facilities must be rapidly established. The latest findings on novel coronavirus disease in patients with end‐stage kidney disease and the guidelines for countermeasures against the spread of novel coronavirus disease worldwide are summarized in this review. |
format | Online Article Text |
id | pubmed-7675310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-76753102020-11-19 Novel coronavirus disease in patients with end‐stage kidney disease Shimada, Noriaki Shimada, Hiroaki Itaya, Yoshiaki Tomino, Yasuhiko Ther Apher Dial Review The novel coronavirus disease outbreak started in Wuhan, China, in December 2019 and has since spread rapidly worldwide. As almost all patients with end‐stage kidney disease have been treated with HD in Japan, they have a higher risk of infection than the healthy population. Moreover, the complications of renal failure, such as hypertension and cardiovascular diseases, appear to be a risk factor of death owing to novel coronavirus disease. The reported morbidity and mortality rates of novel coronavirus disease are significantly higher in dialysis patients than in the healthy population. No treatment for novel coronavirus disease has yet been developed; thus, countermeasures to prevent the spread of coronavirus disease in dialysis facilities must be rapidly established. The latest findings on novel coronavirus disease in patients with end‐stage kidney disease and the guidelines for countermeasures against the spread of novel coronavirus disease worldwide are summarized in this review. John Wiley & Sons Australia, Ltd 2020-10-27 2021-10 /pmc/articles/PMC7675310/ /pubmed/33040443 http://dx.doi.org/10.1111/1744-9987.13599 Text en © 2020 The Authors. Therapeutic Apheresis and Dialysis published by John Wiley & Sons Australia, Ltd on behalf of International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Shimada, Noriaki Shimada, Hiroaki Itaya, Yoshiaki Tomino, Yasuhiko Novel coronavirus disease in patients with end‐stage kidney disease |
title | Novel coronavirus disease in patients with end‐stage kidney disease |
title_full | Novel coronavirus disease in patients with end‐stage kidney disease |
title_fullStr | Novel coronavirus disease in patients with end‐stage kidney disease |
title_full_unstemmed | Novel coronavirus disease in patients with end‐stage kidney disease |
title_short | Novel coronavirus disease in patients with end‐stage kidney disease |
title_sort | novel coronavirus disease in patients with end‐stage kidney disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675310/ https://www.ncbi.nlm.nih.gov/pubmed/33040443 http://dx.doi.org/10.1111/1744-9987.13599 |
work_keys_str_mv | AT shimadanoriaki novelcoronavirusdiseaseinpatientswithendstagekidneydisease AT shimadahiroaki novelcoronavirusdiseaseinpatientswithendstagekidneydisease AT itayayoshiaki novelcoronavirusdiseaseinpatientswithendstagekidneydisease AT tominoyasuhiko novelcoronavirusdiseaseinpatientswithendstagekidneydisease |